UNITED CANNABIS CORP
UNITED CANNABIS CORP (CNAB): 5 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.1 months
D/E -2.74 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for UNITED CANNABIS CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$565K
Quarterly Burn
$2.0M
Runway
1.1 mo
Revenue
$4.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| epidiferphane | Preclinical |
| indermil tissue adhesive | Approved |
| prana bio nutrient medicinals | Preclinical |
| prana bio nutrient medicinals p1 | Phase 1 |
| tresoft ocufilcon soft hydrophilic contact lens | Approved |
Frequently asked questions
How many drug candidates are in UNITED CANNABIS CORP's pipeline?
UNITED CANNABIS CORP (CNAB) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is UNITED CANNABIS CORP's lead drug candidate?
UNITED CANNABIS CORP's most advanced tracked candidate is epidiferphane (Preclinical) for negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer.
What is UNITED CANNABIS CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, UNITED CANNABIS CORP has approximately 1.1 months of cash runway.
Who is the CEO of UNITED CANNABIS CORP?
Earnest Blackmon is the chief executive officer of UNITED CANNABIS CORP (CNAB).
Get the full picture on UNITED CANNABIS CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.